Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

Research

Viral infections and atopy in asthma pathogenesis: New rationales for asthma prevention and treatment

Prospective birth cohort studies tracking asthma initiation and consolidation in community cohorts have identified viral infections occurring against a...

News & Events

The Kids Research Institute Australia researchers share in TPCHRF funding

Eight The Kids Research Institute Australia researchers are among those who have received grant funding from the Telethon-Perth Children’s Hospital Research Fund (TPCHRF).

News & Events

Volunteers needed for world-first trial to prevent asthma

Australian scientists have today launched a world first research trial into a treatment that could prevent asthma in high risk children.

News & Events

NHMRC funding awarded to support child health research

The Kids Research Institute Australia researchers have been awarded more than $10 million in research funding from the National Health and Medical Research Council (NHMRC).

News & Events

Switch on the immune system early

Findings by Professor Pat Holt revealed researchers had been heading down the wrong path in their battle strategy against respiratory allergy and asthma.

News & Events

Overseas trip will help unlock the asthma puzzle

One in ten Australians have asthma and Dr Kimberley Wang from The Kids Research Institute Australia is on a mission to find out what causes it.

Respiratory Environmental Health

The Respiratory Environmental Health team conducts research in early life determinants of lung growth and development, respiratory environmental health, and mechanisms of airway dysfunction in asthma and other respiratory disease.

Research

Association between socioeconomic status and the development of asthma: analyses of income trajectories

Using data on 2868 children born in the Western Australian Pregnancy Cohort (Raine) Study, we examined the association between changes in family...

Research

Real world effectiveness of early ensitrelvir treatment in patients with SARS-CoV-2, a retrospective case series

Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.

Research

Global change, climate change, and asthma in children: Direct and indirect effects - A WAO Pediatric Asthma Committee Report

The twenty-first century has seen a fundamental shift in disease epidemiology with anthropogenic environmental change emerging as the likely dominant factor affecting the distribution and severity of current and future human disease. This is especially true of allergic diseases and asthma with their intimate relationship with the natural environment.